Physician profile
Charlie Srivilasa
NPI 1346531464
$11,072.05
in general payments reported to CMS, 2019-2025
6 companies · $10K in 2025
The $10K reported for 2025 was more than what 96% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2023: $404 · 2024: $229 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $2,506 · Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $2,506.26 |
| Food and Beverage | $1,449.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,905.78 | 2023-2025 | |
| Zimmer Biomet Holdings, INC. | $1,466.92 | 2023-2025 | Advantagerib, Ribfix Titan, Ribfix Blu Advantage |
| Acera Surgical, INC. | $334.63 | 2023-2025 | Restrata Wound Matrix |
| Kerecis Limited | $207.33 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Acell, INC. | $115.92 | 2020 | |
| Ethicon US, LLC | $41.47 | 2024-2025 | Dermabond, Stratafix, Evarrest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlie Srivilasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.